Pricing

BioLine RX Ltd (BLRX)

followers ·
Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Philip A. Serlin
Employees:
40
2 HAMA-AYAN STREET, MODI-IN TECHNOLOGY PARK, MODI-IN, L3, 7177871
972-2-548-9100
Stock Split History
DateRatio
2019-07-15 1:15
Motixafortide, a peptide, has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization. It is also developing AGI-134, an immuno-oncology agent, and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available